


Optimizing Cardiovascular Risk Reduction in High-Risk Patients Through Lipid Management

2017 NLA Expert Panel on Treatment of Clinical ASCVD and Heterozygous FH and with PCSK9 inhibitors



Saeed A, et al. *J Clin Lipidol.* 2017;11(3):596-599.